AIM: The aim of this study was to determine the ciprofloxacin serum concentrations in hospitalized patients and to determine which percentage reached the efficacy target of AUC : MIC > 125. Additionally, the influence of demographic anthropomorphic and clinical parameters on the pharmacokinetics and pharmacodynamics of ciprofloxacin were investigated. METHODS: In serum of 80 hospitalized patients ciprofloxacin concentrations were measured with reverse phase high performance liquid chromatography with fluorescence detection. The ciprofloxacin dose was 400-1200 mg day(-1) i.v. in two or three doses depending on renal function and causative bacteria. Pharmacokinetic parameters were calculated with maximum a posteriori Bayesian estimation (MW\PHARM 3.60). A two compartment open model was used. RESULTS: Mean (± SD) age was 66 (± 17) years, the mean clearance corrected for bodyweight was 0.24 l h(-1) kg(-1) and the mean AUC was 49 mg l(-1) h. Ciprofloxacin clearance and thus AUC were associated with both age and serum creatinine. Of all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin AUC : MIC > 125 target with MICs of 0.25 and 0.5 mg l(-1), respectively. A computer simulated increase in the daily dose from 800 mg to 1200 mg, decreased these percentages to 1% and 37%, respectively. CONCLUSION: A substantial proportion of the hospitalized patients did not reach the target ciprofloxacin AUC : MIC and are suboptimally dosed with recommended doses. Taking into account the increasing resistance to ciprofloxacin worldwide, a ciprofloxacin dose of 1200 mg i.v. daily in patients with normal renal function is necessary to reach the targeted AUC : MIC > 125.
AIM: The aim of this study was to determine the ciprofloxacin serum concentrations in hospitalized patients and to determine which percentage reached the efficacy target of AUC : MIC > 125. Additionally, the influence of demographic anthropomorphic and clinical parameters on the pharmacokinetics and pharmacodynamics of ciprofloxacin were investigated. METHODS: In serum of 80 hospitalized patientsciprofloxacin concentrations were measured with reverse phase high performance liquid chromatography with fluorescence detection. The ciprofloxacin dose was 400-1200 mg day(-1) i.v. in two or three doses depending on renal function and causative bacteria. Pharmacokinetic parameters were calculated with maximum a posteriori Bayesian estimation (MW\PHARM 3.60). A two compartment open model was used. RESULTS: Mean (± SD) age was 66 (± 17) years, the mean clearance corrected for bodyweight was 0.24 l h(-1) kg(-1) and the mean AUC was 49 mg l(-1) h. Ciprofloxacin clearance and thus AUC were associated with both age and serum creatinine. Of all patients, 21% and 75% of the patients, did not reach the proposed ciprofloxacin AUC : MIC > 125 target with MICs of 0.25 and 0.5 mg l(-1), respectively. A computer simulated increase in the daily dose from 800 mg to 1200 mg, decreased these percentages to 1% and 37%, respectively. CONCLUSION: A substantial proportion of the hospitalized patients did not reach the target ciprofloxacin AUC : MIC and are suboptimally dosed with recommended doses. Taking into account the increasing resistance to ciprofloxacin worldwide, a ciprofloxacin dose of 1200 mg i.v. daily in patients with normal renal function is necessary to reach the targeted AUC : MIC > 125.
Authors: Jean-Marie Conil; Bernard Georges; Anne de Lussy; Dalia Khachman; Thierry Seguin; Stéphanie Ruiz; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin Journal: Int J Antimicrob Agents Date: 2008-09-02 Impact factor: 5.283
Authors: Arthur R H van Zanten; Kees H Polderman; Ingeborg M van Geijlswijk; Gert Y G van der Meer; Marinus A Schouten; Armand R J Girbes Journal: J Crit Care Date: 2008-04-18 Impact factor: 3.425
Authors: A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag Journal: Antimicrob Agents Chemother Date: 1993-05 Impact factor: 5.191
Authors: Dong-Jin Lim; Daniel Skinner; John Mclemore; Nick Rivers; Jeffrey Brent Elder; Mark Allen; Connor Koch; John West; Shaoyan Zhang; Harrison M Thompson; Justin P McCormick; Jessica W Grayson; Do-Yeon Cho; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2019-11-06 Impact factor: 3.858
Authors: Do-Yeon Cho; Dong-Jin Lim; Calvin Mackey; Christopher G Weeks; Jaime A Peña Garcia; Daniel Skinner; Shaoyan Zhang; Justin McCormick; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2019-01-31 Impact factor: 3.858
Authors: Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Hajira Bilal; Phillip J Bergen; Jessica R Tait; Steven C Wallis; Anton Y Peleg; Jason A Roberts; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Brigitta Kurenbach; Delphine Marjoshi; Carlos F Amábile-Cuevas; Gayle C Ferguson; William Godsoe; Paddy Gibson; Jack A Heinemann Journal: MBio Date: 2015-03-24 Impact factor: 7.867